Motor, Non-motor and Genetic Determinants of Progression and Complications in Parkinson's Disease: A Multicenter Cohort Study in Mexican Population (ReMePArk)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson's Disease
- Sponsor
- El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
- Enrollment
- 550
- Locations
- 6
- Primary Endpoint
- To assess motor scale change over time
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The objective of the study is to assess the effect of motor, non-motor and genetic factors on the progression of Parkinson's disease as well as its impact on complications rates.
A large sample of Mexican subjects with Parkinson's disease attending several referral centers will be included.
Data collected will include disease severity and motor scales, non-motor scales as well as genotyping for monogenic forms of the disease.
Assessments will be performed every 6 months for two years.
Detailed Description
Demographic and clinical data will be collected after obtaining a signed informed consent. Recruitment will be competitive. Data collected includes age, gender, motor phenotype, age at onset, age at diagnosis, smoking history, family history, antiparkinsonic treatment, other treatments and a complete neurological evaluation.
Investigators
Amin Cervantes-Arriaga
MD, MSc
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of Parkinson's disease by the United Kingdom Parkinson's disease Society Brain Bank Criteria
- •Any gender
- •Any Hoehn and Yahr stage
- •Written informed consent
Exclusion Criteria
- •Severe comorbidity that may limit proper neurological evaluation as judged by the investigator
- •Subjects with atypical or secondary parkinsonism
Outcomes
Primary Outcomes
To assess motor scale change over time
Time Frame: Every 6 months for 2 years
Motor symptoms will be assessed by proper and validated motor scales; also minimal clinically important change will be determined.
Secondary Outcomes
- To assess caregiver burden as disease progresses(Every 12 months for 2 years)
- To assess quality of life change over time.(Every 6 months for 2 years)
- To assess non-motor symptoms over time(Every 6 months for 2 years)